Search research articles
Contact Us
Filters
Showing results (41-50 of 289) with videos related to
Page
of 29
Sort By:
Therapeutic Advances in Urology
|
July 2, 2021
Second-line treatment in renal cell carcinoma: clinical experience and decision making
Valentina Guadalupi, Giacomo Cartenì, Roberto Iacovelli, et al.
JAMA Network Open
|
March 6, 2024
Significance of PD-L1 in Metastatic Urothelial Carcinoma Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis
Brigida Anna Maiorano, Massimo Di Maio, Linda Cerbone, et al.
Tumori
|
May 5, 2020
Use of a natural multicomponent mouthwash plus oral hygiene vs oral hygiene alone to prevent everolimus-induced stomatitis: the STOP multicenter, randomized trial
Camillo Porta, Elena Verzoni, Silvia Zai, et al.
European Journal of Cancer (Oxford, England : 1990)
|
July 27, 2020
Patients with sarcomatoid renal cell carcinoma - re-defining the first-line of treatment: A meta-analysis of randomised clinical trials with immune checkpoint inhibitors
Roberto Iacovelli, Chiara Ciccarese, Emilio Bria, et al.
Tumori
|
December 7, 2022
BONSAI-2 study: Nivolumab as therapeutic option after cabozantinib failure in metastatic collecting duct carcinoma patients
Sebastiano Buti, Francesca Trentini, Pierangela Sepe, et al.
ESMO Open
|
March 30, 2020
Bone health management in the continuum of prostate cancer disease: a review of the evidence with an expert panel opinion
Daniele Santini, Alfredo Berruti, Massimo Di Maio, et al.
Clinical Genitourinary Cancer
|
June 25, 2013
Prognostic role of pancreatic metastases from renal cell carcinoma: results from an Italian center
Paolo Grassi, Elena Verzoni, Luigi Mariani, et al.
Tumori
|
March 29, 2014
Rationale and protocol of RESORT, a randomized, open-label, multicenter phase II study to evaluate the efficacy of sorafenib in patients with advanced renal cell carcinoma after radical resection of the metastases
Giuseppe Procopio, Elena Verzoni, Pamela Biondani, et al.
Expert Opinion on Drug Safety
|
March 20, 2014
Axitinib safety in metastatic renal cell carcinoma: suggestions for daily clinical practice based on case studies
Sergio Bracarda, Daniel Castellano, Giuseppe Procopio, et al.
Tumori
|
June 15, 2007
Renal cell cancer and sorafenib: skin toxicity and treatment outcome
Emilio Bajetta, Giuseppe Procopio, Elena Verzoni, et al.
Page
of 29
Search research articles
Search
Showing results (41-50 of 289) with videos related to
Sort By:
Page
of 29
Therapeutic Advances in Urology
|
July 2, 2021
Second-line treatment in renal cell carcinoma: clinical experience and decision making
Valentina Guadalupi, Giacomo Cartenì, Roberto Iacovelli, et al.
JAMA Network Open
|
March 6, 2024
Significance of PD-L1 in Metastatic Urothelial Carcinoma Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis
Brigida Anna Maiorano, Massimo Di Maio, Linda Cerbone, et al.
Tumori
|
May 5, 2020
Use of a natural multicomponent mouthwash plus oral hygiene vs oral hygiene alone to prevent everolimus-induced stomatitis: the STOP multicenter, randomized trial
Camillo Porta, Elena Verzoni, Silvia Zai, et al.
European Journal of Cancer (Oxford, England : 1990)
|
July 27, 2020
Patients with sarcomatoid renal cell carcinoma - re-defining the first-line of treatment: A meta-analysis of randomised clinical trials with immune checkpoint inhibitors
Roberto Iacovelli, Chiara Ciccarese, Emilio Bria, et al.
Tumori
|
December 7, 2022
BONSAI-2 study: Nivolumab as therapeutic option after cabozantinib failure in metastatic collecting duct carcinoma patients
Sebastiano Buti, Francesca Trentini, Pierangela Sepe, et al.
ESMO Open
|
March 30, 2020
Bone health management in the continuum of prostate cancer disease: a review of the evidence with an expert panel opinion
Daniele Santini, Alfredo Berruti, Massimo Di Maio, et al.
Clinical Genitourinary Cancer
|
June 25, 2013
Prognostic role of pancreatic metastases from renal cell carcinoma: results from an Italian center
Paolo Grassi, Elena Verzoni, Luigi Mariani, et al.
Tumori
|
March 29, 2014
Rationale and protocol of RESORT, a randomized, open-label, multicenter phase II study to evaluate the efficacy of sorafenib in patients with advanced renal cell carcinoma after radical resection of the metastases
Giuseppe Procopio, Elena Verzoni, Pamela Biondani, et al.
Expert Opinion on Drug Safety
|
March 20, 2014
Axitinib safety in metastatic renal cell carcinoma: suggestions for daily clinical practice based on case studies
Sergio Bracarda, Daniel Castellano, Giuseppe Procopio, et al.
Tumori
|
June 15, 2007
Renal cell cancer and sorafenib: skin toxicity and treatment outcome
Emilio Bajetta, Giuseppe Procopio, Elena Verzoni, et al.
Page
of 29